A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies
Study of LAG525 Alone and in Combination with PDR001 in Patients with Advanced Malignancies
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAP4008
U.S. Govt. ID: NCT02460224
Contact: Richard Carvajal, MD: 646-317-6041 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is to identify the best dose of the study drugs that can be safely given to patients with cancer. The study will also evaluate how well the study drugs work in patients with cancer. The study drugs are LAG525 and PDR001. LAG525 will be given alone or in combination with PDR001.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a solid tumor that continues to grow or spread? Yes No
Have you had treatment before? Or, is there no standard therapy for your disease? Yes No
Are you willing to have additional biopsies while on study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal, MD
rdc2150@cumc.columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE